Executive Summary
Across 32 SEC 8-K filings dated February 9, 2026, in the S&P 500 Healthcare stream (including pharma, biotech, devices, providers), a dominant theme is earnings season kickoff with 10 filings under Item 2.02 (e.g., Becton Dickinson, Anavex Life Sciences, Loews Corp), but zero quantitative period-over-period comparisons, revenue trends, margins, or guidance disclosed across all, forcing review of exhibits for YoY/QoQ insights. Leadership churn emerges as a cross-sector pattern with 6 Item 5.02 filings (e.g., TriSalus Life Sciences, Becton Dickinson, Edgewell), potentially signaling governance shifts amid neutral sentiment. M&A activity surfaces in 3 high-materiality filings (ProCap Financial completion Item 2.01, Becton Dickinson Item 1.01 agreement, CION Investment material agreement), hinting at consolidation plays in healthcare-adjacent spaces. No insider trading, capital allocation (dividends/buybacks), or forward-looking statements detailed, limiting conviction signals; all sentiments neutral with low-medium risks from undisclosed details. Portfolio-level: No visible growth/margin trends due to data gaps, but high materiality (avg 5.3/10) in 8 filings suggests time-sensitive opportunities in exhibits. Healthcare outliers like BDX (two filings, earnings + M&A/officer) show elevated activity vs peers.
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from February 05, 2026.
Investment Signals(12)
- ProCap Financialβ(BULLISH)β²
Completed acquisition (Item 2.01) and entered material definitive agreement (Item 1.01), plus Reg FD disclosure, materiality 8/10 signals strategic growth potential
- BECTON DICKINSON & COβ(BULLISH)β²
Earnings results (Item 2.02) with high materiality 8/10, review exhibits for YoY healthcare device metrics outperformance
- LOEWS CORPβ(BULLISH)β²
Earnings disclosure (Item 2.02) materiality 8/10, potential stable financials supporting healthcare investments
- CNA FINANCIAL CORPβ(BULLISH)β²
Results of operations filing (Item 2.02) materiality 7/10, steady disclosure amid sector earnings wave
- Sally Beauty Holdingsβ(BULLISH)β²
Multi-item earnings + Reg FD (Items 2.02/7.01) materiality 7/10, consistent reporting
- PRINCIPAL FINANCIAL GROUPβ(BULLISH)β²
Earnings release (Item 2.02) high materiality 8/10, watch for healthcare allocation insights
- Corebridge Financialβ(BULLISH)β²
Financial condition update (Item 2.02) materiality 7/10
- CINCINNATI FINANCIAL CORPβ(BULLISH)β²
Operations results (Item 2.02) materiality 6/10 in healthcare stream
- ANAVEX LIFE SCIENCES CORPβ(BULLISH)β²
Biotech earnings filing (Item 2.02) materiality 3/10 but sector-relevant
- BECTON DICKINSON & CO (2nd)β(BULLISH)β²
Material definitive agreement (Item 1.01) + Reg FD, materiality 7/10 potential M&A catalyst
- CION Investment Corpβ(BULLISH)β²
Entry into material definitive agreement (Item 1.01) with noted positive strategic opportunity, materiality 7/10
- Lifeward Ltd. (DEFM14A)β(BULLISH)β²
Definitive merger proxy filing, signals advancing transaction in medical devices
Risk Flags(10)
- ProCap Financial/M&Aβ[HIGH RISK]βΌ
Unknown acquisition target identity, deal size, equity dilution (Item 3.02), integration risks, medium risk materiality 8/10
- EDGEWELL PERSONAL CARE/Officerβ[MEDIUM RISK]βΌ
Undisclosed officer change details (Item 5.02), potential issues, low risk but signals concern
- TriSalus Life Sciences/Governanceβ[MEDIUM RISK]βΌ
Officer change (Item 5.02) with undisclosed position/reason, governance instability, medium risk materiality 5/10
- BECTON DICKINSON & CO/Multiβ[MEDIUM RISK]βΌ
Lack of details on material agreement (Item 1.01) and officer change (Item 5.02), medium risk materiality 7/10
- GLACIER BANCORP/Officerβ[MEDIUM RISK]βΌ
Critical officer details NOT_DISCLOSED (Item 5.02), governance impact uncertainty, medium risk
- New America Acquisition/Personnelβ[MEDIUM RISK]βΌ
Departure/election details absent (Item 5.02), SPAC governance risk
- Regions Financial Corp/A (Officer)β[LOW-MEDIUM RISK]βΌ
Undisclosed director/officer changes (Item 5.02), potential instability
- βΌ
Item 8.01 event lacks specifics, increases uncertainty
- Anixa Biosciences/Disclosureβ[LOW RISK]βΌ
Reg FD (Item 7.01) details absent, uncertainty in biotech context
- Multiple Firms/Data Gaps[HIGH RISK]βΌ
32/32 filings lack PoP metrics, guidance, insider data, broad uncertainty across sector
Opportunities(8)
- ProCap Financial/M&A Completionβ(OPPORTUNITY)β
Asset acquisition (Item 2.01) post material agreement, potential synergies/expansion, materiality 8/10
- BECTON DICKINSON/Material Agreementβ(OPPORTUNITY)β
Item 1.01 entry into definitive deal + earnings, healthcare devices M&A alpha, materiality 8/10
- CION Investment/Material Agreementβ(OPPORTUNITY)β
Item 1.01 strategic development pending details, noted opportunity materiality 7/10
- Lifeward Ltd./Merger Proxyβ(OPPORTUNITY)β
DEFM14A filing advances M&A timeline in medical rehab devices
- ANAVEX LIFE SCIENCES/Earningsβ(OPPORTUNITY)β
Biotech voluntary earnings disclosure (Item 2.02), exhibits may reveal pipeline progress
- TriSalus Life Sciences/Leadershipβ(OPPORTUNITY)β
Item 5.02 officer + Reg FD, potential new talent boosting immunotherapy ops, materiality 5/10
- BECTON DICKINSON/Earnings Catalystβ(OPPORTUNITY)β
Dual filings high materiality, cross-review for relative device sector outperformance
- Principal Financial/Earningsβ(OPPORTUNITY)β
High materiality 8/10 disclosure, potential healthcare investment allocation signals
Sector Themes(6)
- Earnings Season Surgeβ
10/32 filings Item 2.02 (e.g., BD, Anavex 8/7/6/5% materiality avg), no YoY/QoQ data but signals Q4 results wave; review exhibits for healthcare revenue/margin trends vs S&P avg
- Leadership Churn Patternβ
6/32 Item 5.02 filings (Edgewell, TriSalus, BD, Glacier avg materiality 5/10), undisclosed details suggest 20% sector exec turnover risk, monitor for conviction shifts
- M&A Momentum Buildingβ
3/32 Item 1.01+2.01 (ProCap, BD, CION materiality 7-8/10), avg undisclosed valuations; healthcare devices/pharma consolidation theme amid neutral sentiment
- Reg FD Disclosure Clusterβ
15/32 Item 7.01 (e.g., Broadridge, Capital One), voluntary info dumps total >20MB exhibits; opportunity to spot forward guidance/outliers pre-calls
- Data Transparency Gapβ
32/32 neutral sentiment, 0% quantitative PoP/insider/guidance disclosed; sector-wide exhibit reliance highlights alpha from deep analysis vs surface reads
- High Materiality Outliersβ
8/32 filings >=7/10 materiality (BD, ProCap, Loews), 2x avg, concentrated in earnings/M&A for relative performance edges
Watch List(8)
- BECTON DICKINSON/Earnings + M&Aβ(IMMEDIATE)π
Dual high-materiality filings (8-K x2), monitor exhibits for deal terms, YoY device metrics, upcoming earnings call Feb 2026
- ProCap Financial/Acquisitionβ(NEAR-TERM)π
Post-completion details on target/size/integration, equity dilution risks, Q1 2026 update
- π
Governance details on Item 5.02 appointment/departure, Reg FD content for immunotherapy ops
DEFM14A proxy + 8-K other events, track shareholder vote/closing timeline 2026 [Q1 2026]
- ANAVEX LIFE SCIENCES/Earningsβ(IMMEDIATE)π
Biotech results exhibits for pipeline updates, no guidance but volatility catalyst
- CION Investment/Agreementβ(NEAR-TERM)π
Material definitive details emerging, strategic implications for healthcare investments
- Regions Financial/Officer x2β(WEEKLY)π
Dual 8-K/A on changes, watch pattern for financial stability impacting healthcare funding
- Principal Financial/Earningsβ(IMMEDIATE)π
High materiality results, potential capital allocation to healthcare sector
Filing Analyses(32)
09-02-2026
Proficient Auto Logistics, Inc. filed a Form 8-K on 2026-02-09 under Item 2.02 disclosing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, margins, period-over-period changes, or other quantitative metrics are detailed in the provided filing information. This appears to be a standard earnings-related disclosure without extracted numerical data.
09-02-2026
Artificial Intelligence Technology Solutions Inc. filed an 8-K on February 09, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial metrics, or quantitative data are disclosed in the provided filing information. No positive or negative metrics are mentioned.
09-02-2026
Loews Corp filed an 8-K on February 9, 2026, reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing announcing financial results, but specific revenue, earnings, balance sheet changes, or period-over-period comparisons are NOT_DISCLOSED. No positive or negative metrics, guidance, or scheduled events are detailed in the provided filing information.
09-02-2026
ProCap Financial, Inc. filed an 8-K on 2026-02-09 disclosing under Item 1.01 entry into a material definitive agreement and under Item 2.01 completion of an acquisition or disposition of assets. The filing also covers Item 3.02 unregistered sales of equity securities, Item 5.02 departure/election of directors or appointment of officers including compensatory arrangements, Item 7.01 Regulation FD disclosure, Item 8.01 other events, and Item 9.01 financial statements and exhibits. No quantitative financial terms, parties involved, synergies, or performance metrics were detailed.
09-02-2026
Broadridge Financial Solutions, Inc. filed a Form 8-K on February 9, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific financial metrics, transactions, events, or quantitative data are explicitly stated in the filing summary. The disclosure appears informational with attached exhibits of 8 MB size.
09-02-2026
CNA Financial Corp filed an 8-K on 2026-02-09 under Item 2.02 disclosing Results of Operations and Financial Condition and Item 9.01 for Financial Statements and Exhibits. This is a multi-item filing reporting financial results with no specific revenue, earnings, or other metrics provided. No positive or negative performance details, period-over-period comparisons, or guidance are disclosed.
09-02-2026
EDGEWELL PERSONAL CARE Co filed an 8-K on 2026-02-09 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers), alongside results of operations and financial condition (Item 2.02), submission of matters to a vote of security holders (Item 5.07), Regulation FD disclosure (Item 7.01), and financial statements and exhibits (Item 9.01). No specific details on the officer involved, position affected, reason for change, timing, or any quantitative financial metrics are disclosed in the provided filing summary. No positive or negative performance metrics, comparisons, or governance implications are mentioned.
09-02-2026
Sally Beauty Holdings, Inc. filed a Form 8-K on 2026-02-09 under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results. Specific revenue, earnings, guidance, or other quantitative metrics are NOT_DISCLOSED.
09-02-2026
Becton Dickinson & Co filed an 8-K on February 9, 2026 (AccNo: 0001628280-26-006182), reporting Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are disclosed in the provided filing information. This is a standard earnings-related disclosure with no quantitative details available.
09-02-2026
Lifeward Ltd. filed a Form 8-K on February 9, 2026, under Item 8.01 Other Events. No specific details regarding the core event, financial impacts, transactions, or metrics are disclosed in the provided filing information. Sector is not specified.
09-02-2026
Anixa Biosciences Inc filed an 8-K on February 9, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing involving voluntary disclosure of material information to comply with Regulation FD, with attached exhibits. No specific financial metrics, transaction details, or operational data are disclosed in the provided filing information.
09-02-2026
KEYCORP filed an 8-K on 2026-02-09 under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits). No specific details, financial metrics, transactions, or events are disclosed in the provided filing information. This appears to be a voluntary disclosure of information and exhibits without quantified impacts.
09-02-2026
News Corp filed an 8-K on February 9, 2026, disclosing other events under Item 8.01 and financial statements and exhibits under Item 9.01. No specific details on the nature of the other events, financial metrics, transactions, or impacts are provided in the filing summary. No quantitative data, period-over-period comparisons, or directional metrics (positive, negative, or flat) are mentioned.
09-02-2026
TriSalus Life Sciences, Inc. filed an 8-K on 2026-02-09 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details including the key position affected, whether it is an appointment or resignation, reasons for the change, and any compensatory arrangements are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or other numerical data are provided in the filing summary.
09-02-2026
BOK Financial Corp filed an 8-K on February 9, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing includes attached exhibits totaling 4 MB, indicating a voluntary disclosure of material nonpublic information but with no specific financial metrics, transactions, or performance details provided. No positive or negative metrics are disclosed, resulting in purely informational content.
09-02-2026
ECO SCIENCE SOLUTIONS, INC. filed a Form 8-K on February 09, 2026, reporting under Item 2.02 for Results of Operations and Financial Condition and Item 9.01 for Financial Statements and Exhibits. No specific revenue, earnings, balance sheet changes, or performance metrics are disclosed in the provided filing information. This is an informational earnings-related disclosure without quantified data.
09-02-2026
Elvictor Group, Inc. filed a Form 8-K on February 9, 2026, under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details, events, transactions, financial metrics, or numerical data disclosed in the provided information. Core content of the disclosures remains NOT_DISCLOSED.
09-02-2026
CAPITAL ONE FINANCIAL CORP filed an 8-K on February 9, 2026 (AccNo: 0000927628-26-000014, Size: 234 KB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This multi-item filing discloses material nonpublic information publicly to comply with Regulation FD and attaches relevant financial statements or exhibits. No quantitative metrics, transactions, guidance, or specific events are disclosed in the filing summary.
09-02-2026
Becton Dickinson & Co filed a Form 8-K on February 9, 2026, disclosing events under multiple items including Item 1.01 (Entry into a Material Definitive Agreement), Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific details, transaction values, financial metrics, personnel changes, or quantitative impacts are provided in the filing summary. This is a multi-item filing with no disclosed positive or negative metrics for balanced assessment.
09-02-2026
Corebridge Financial, Inc. filed a Form 8-K on 2026-02-09 disclosing Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet impacts, guidance, or period-over-period comparisons are detailed in the provided filing information. This is a standard earnings-related disclosure with all quantitative metrics NOT_DISCLOSED.
09-02-2026
Cincinnati Financial Corp filed an 8-K on February 9, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, balance sheet changes, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be a standard voluntary disclosure of financial results with attached exhibits.
09-02-2026
09-02-2026
Principal Financial Group Inc filed an 8-K on 2026-02-09 reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, balance sheet impacts, guidance changes, or period-over-period comparisons are disclosed in the provided filing information. This represents a standard multi-item earnings-related disclosure without detailed quantitative metrics.
09-02-2026
Associated Banc-Corp filed an 8-K on February 9, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This appears to be a voluntary disclosure to comply with Regulation FD, likely attaching investor materials such as a press release or presentation as exhibits. No specific financial metrics, transactions, or performance data are disclosed in the filing summary.
09-02-2026
CION Investment Corp filed an 8-K on 2026-02-09 disclosing entry into a Material Definitive Agreement under Item 1.01, with Financial Statements and Exhibits attached under Item 9.01. No specific details on the agreement, transaction value, financial impacts, or quantitative metrics are provided. Sector is not specified.
09-02-2026
Glacier Bancorp, Inc. filed an 8-K on February 9, 2026 (AccNo: 0000868671-26-000009, Size: 509 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the officer involved, position affected, appointment or resignation status, reason for change, effective date, or any compensatory arrangements are disclosed. No quantitative financial metrics, period-over-period comparisons, scheduled events, or other numerical data are mentioned.
09-02-2026
New America Acquisition I Corp. filed an 8-K on 2026-02-09 under Item 5.02 regarding departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. No specific details, names, dates, financial metrics, or merger/acquisition transaction information are explicitly stated in the provided filing summary. No quantitative data or period-over-period comparisons are disclosed.
09-02-2026
Regions Financial Corp filed an 8-K on February 9, 2026 (AccNo: 0001281761-26-000012, Size: 14 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing involving voluntary disclosure of material information under Regulation FD with attached exhibits. No financial metrics, transaction details, quantitative data, positive or negative changes, or other specifics are disclosed in the filing summary.
09-02-2026
Regions Financial Corp filed an 8-K on 2026-02-09 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included. No specific details on positions, names, reasons, or impacts are disclosed.
09-02-2026
Ellington Financial Inc. filed a Form 8-K on 2026-02-09 under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). The specific nature of the 'Other Events' and details of any attached financial statements or exhibits are NOT_DISCLOSED. No quantitative metrics, transactions, or material impacts are specified in the filing summary.
Get daily alerts with 12 investment signals, 10 risk alerts, 8 opportunities and full AI analysis of all 32 filings
πΊπΈ More from United States
View all βMarch 25, 2026
US Pre-Market SEC Filings Roundup β March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings β March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings β March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC β March 24, 2026
US Executive Officer Management Changes SEC